194 related articles for article (PubMed ID: 12207609)
21. Trichomegaly following treatment with gefitinib (ZD1839).
Pascual JC; Bañuls J; Belinchon I; Blanes M; Massuti B
Br J Dermatol; 2004 Nov; 151(5):1111-2. PubMed ID: 15541102
[No Abstract] [Full Text] [Related]
22. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Barker AJ; Gibson KH; Grundy W; Godfrey AA; Barlow JJ; Healy MP; Woodburn JR; Ashton SE; Curry BJ; Scarlett L; Henthorn L; Richards L
Bioorg Med Chem Lett; 2001 Jul; 11(14):1911-4. PubMed ID: 11459659
[TBL] [Abstract][Full Text] [Related]
23. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
Santiago F; Gonçalo M; Reis JP; Figueiredo A
An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
[TBL] [Abstract][Full Text] [Related]
24. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
Busam KJ; Capodieci P; Motzer R; Kiehn T; Phelan D; Halpern AC
Br J Dermatol; 2001 Jun; 144(6):1169-76. PubMed ID: 11422037
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib-induced dermatologic side-effects.
Bovenschen HJ; Alkemade JA
Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
[No Abstract] [Full Text] [Related]
27. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Herbst RS
Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
[TBL] [Abstract][Full Text] [Related]
28. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Pascual JC; Belinchón I; Sivera F; Yuste A
Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
[No Abstract] [Full Text] [Related]
29. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B
Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903
[No Abstract] [Full Text] [Related]
30. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Seiverling EV; Fernanadez EM; Adams D
J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
[TBL] [Abstract][Full Text] [Related]
32. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
[TBL] [Abstract][Full Text] [Related]
33. Rosaceiform eruption induced by erlotinib.
Patrizi A; Bianchi F; Neri I
Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
[TBL] [Abstract][Full Text] [Related]
34. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab-induced acneiform eruption and the response to isotretinoin.
Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
[No Abstract] [Full Text] [Related]
36. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
[TBL] [Abstract][Full Text] [Related]
37. [Acneiform eruptions induced by cetuximab].
Walon L; Gilbeau C; Lachapelle JM
Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
[TBL] [Abstract][Full Text] [Related]
38. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
39. Exfoliative eruption secondary to gefitinib (ZD1839).
Becuwe C; Dalle S; Arpin D; Balme B; Thomas L
Dermatology; 2007; 215(3):266-8. PubMed ID: 17823530
[No Abstract] [Full Text] [Related]
40. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]